content

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance’s AMTAGVI for Advanced Melanoma

WuXi Advanced Therapies , a wholly owned subsidiary of WuXi AppTec announced that the U.S. FDA has approved its Philadelphia site to begin the...

Ginkgo, SaponiQx Awarded $31M to Develop Next-Gen Vaccine Adjuvants

The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program has awarded, through the...

Azzur Group Expands Service Portfolio with Analytical Services for Advanced Therapeutics, Enhancing the Discovery to Delivery Platform

There are currently more than 3,000 advanced therapies in the development pipeline globally, along with 124 approved therapies. To enable this innovation and transformation...

Resilience Expands Clinical and Commercial Drug Product Manufacturing Capabilities and Capacities

National Resilience, Inc. (Resilience), Expands Clinical and Commercial Drug Product Manufacturing Capabilities and CapacitiesNational Resilience, Inc. , a technology-focused biomanufacturing company dedicated to broadening...

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

AstraZeneca announced the successful completion of the acquisition of Gracell Biotechnologies Inc , a global clinical-stage biopharmaceutical company developing innovative cell therapies for the...

AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology

AbbVie Inc. and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and...

Viatris Receives Global Minimized Risk of Antimicrobial Resistance Certification, Advancing its Commitment to Responsible Antibiotic Production

Viatris Inc. a global healthcare company, announced that its Aurangabad, India, facility has received certification from the British Standards Institution (BSI) for meeting a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read